Website
N/ATelephone
N/A
Address
Description
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.29 - 0.59
Trade Value (12mth)
AU$6,501.00
1 week
11.11%
1 month
49.25%
YTD
16.28%
1 year
-1.96%
All time high
1.02
EPS 3 yr Growth
957.700%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-41.30%
ROIC
-60.30%
Interest Coverage
N/A
Quick Ratio
5.10
Shares on Issue (Fully Dilluted)
88m
HALO Sector
Healthcare
Next Company Report Date
21-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 May 23 |
Trading Halt
×
Trading Halt |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 December 21 |
Application for quotation of securities - AGN
×
Application for quotation of securities - AGN |
30 November 23 |
Appointment of Non-Executive Chair
×
Appointment of Non-Executive Chair |
30 November 22 |
Notification regarding unquoted securities - AGN
×
Notification regarding unquoted securities - AGN |
30 November 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
30 March 23 |
Significant Non-Dilutive Funding For Preclinical HIE Studies
×
Significant Non-Dilutive Funding For Preclinical HIE Studies |
30 March 22 |
Positive Preclincal Data on Efficacy in New Indication
×
Positive Preclincal Data on Efficacy in New Indication |
29 September 23 |
Date of AGM & Closing Date For Director Nominations
×
Date of AGM & Closing Date For Director Nominations |
29 September 22 |
Further Positive Preclinical Results for ARG-007 In HIE
×
Further Positive Preclinical Results for ARG-007 In HIE |
29 July 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 February 23 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
28 February 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
27 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
27 October 23 |
Board Update
×
Board Update |
27 October 21 |
Investor Presentation
×
Investor Presentation |
27 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
27 August 21 |
Appendix 4E & Annual Report 30 June 2021
×
Appendix 4E & Annual Report 30 June 2021 |
27 April 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 October 22 |
No Serious Safety Issues Observed in First Cohort
×
No Serious Safety Issues Observed in First Cohort |
26 April 22 |
Maximum Tolerated Dose Successfully Established in Studies
×
Maximum Tolerated Dose Successfully Established in Studies |
25 October 23 |
Investor Presentation
×
Investor Presentation |
25 November 22 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
25 November 22 |
AGM Presentation
×
AGM Presentation |
25 November 22 |
Phase 1 Clinical Trial Progress Update
×
Phase 1 Clinical Trial Progress Update |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.